Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3062]

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Effectiveness of a cardiovascular health EHR application for cancer survivors...

Prof Kathryn Weaver - Wake Forest School of Medicine, Winston-Salem, USA

Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice ( Prof Kathryn Weaver - Wake Forest School of Medicine, Winston-Salem, USA )

ASCO 2023: Head and neck highlights

Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA

ASCO 2023: Head and neck highlights ( Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA )

Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to...

Dr Brian Van Tine - Washington University in St Louis, St Louis, USA

Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to cabozantinib alone in soft tissue sarcoma ( Dr Brian Van Tine - Washington University in St Louis, St Louis, USA )

Baseline liquid biopsy results in treatment efficacy of FOLFIRI/cetuximab in...

Prof Sebastian Stintzing - Universitätsmedizin Berlin, Berlin, Germany

Baseline liquid biopsy results in treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC ( Prof Sebastian Stintzing - Universitätsmedizin Berlin, Berlin, Germany )

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment

Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment ( Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA )

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab...

Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma ( Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA )

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active...

Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL ( Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan )

Adding ribociclib to endocrine therapy shows an improvement in invasive disease...

Prof Dennis Slamon - UCLA, Los Angeles, USA

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients ( Prof Dennis Slamon - UCLA, Los Angeles, USA )

Nine-weeks trastuzumab still effective compared with one year trastuzumab for...

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment...

Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer ( Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan )

NSIA and Nigeria to improve treatment for Nigerians through the building of new...

Aminu Umar-Sadiq - MD & CEO, Nigeria Sovereign Investment Authority (NSIA)

NSIA and Nigeria to improve treatment for Nigerians through the building of new cancer centres ( Aminu Umar-Sadiq - MD & CEO, Nigeria Sovereign Investment Authority (NSIA) )

More from ecancer